Objective  To analyze the evolutionary trends and academic hotspots in research related to cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke based on bibliometrics and provide references for future research directions.

Methods  Relevant literature on cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke was retrieved from Web of Science Core Collection database. VOSviewer 1.6.18, Pajek 64 5.16, CiteSpace 6.3.R1 and R 4.4.3 software was used to perform visual analysis on the countries, institutions, authors, and keywords of the published papers.

Results  A total of 4 477 articless were included. The annual publication volume showed a fluctuating growth trend. The United States was the country with the highest number of publications (1 528 articles), followed by China (644 articles). Harvard University was the foreign institution with the highest number of publications (116 articles), and Capital Medical University was the institution in China with the highest number of publications (74 articles). Deepak L Bhatt was the author with the highest number of publications (31 articles). Currently, research mainly focused on the fields of biological and medical sciences, with clinical research being the dominant type. The top five keywords by frequency were cardiovascular diseases, atherosclerosis, risk factors, ischemic stroke, and diabetes mellitus. Over the past decade, emerging keywords such as depression, platelet, aging, statins, and Alzheimer's disease had emerged.

Conclusion  Currently, research related to cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke remains highly active. Further research is needed at the cellular and molecular levels, as well as on the co- morbidity of cardiovascular and cerebrovascular diseases. The connection between emerging topics such as aging or neurodegenerative diseases and cardiovascular and cerebrovascular diseases requires in-depth exploration.

1.刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管杂志, 2024, 29(4): 305-324. [Liu MB, He XY, Yang XH, et al. Interpretation of report on cardiovascular health and diseases in China 2023[J]. Chinese Journal of Cardiovascular Medicine, 2024, 29(4): 305-324.] DOI: 10.3969/j.issn.1007-5410.2024.04.002.

2.Wang H, Zhang H, Zou Z. Changing profiles of cardiovascular disease and risk factors in China: a secondary analysis for the Global Burden of Disease Study 2019[J]. Chin Med J (Engl), 2023, 136(20): 2431-2441. DOI: 10.1097/CM9.0000000000002741.

3.Liu Q, Zhao J, Wang S. From cerebrovascular diseases to neuro-co-cardiological diseases: a challenge in the new epoch[J]. Sci Bull (Beijing), 2022, 67(18): 1830-1832. DOI: 10.1016/j.scib.2022.08.013.

4.Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019, 234(10): 16812-16823. DOI: 10.1002/jcp.28350.

5.Hilkens NA, Casolla B, Leung TW, et al. Stroke[J]. Lancet, 2024, 403(10446): 2820-2836. DOI: 10.1016/S0140-6736(24)00642-1.

6.Libby P, Theroux P. Pathophysiology of coronary artery disease[J]. Circulation, 2005, 111(25): 3481-3488. DOI: 10.1161/CIRCULATIONAHA.105.537878.

7.Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14): 1289-1367. DOI: 10.1093/eurheartj/ehaa575.

8.Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2021, 144(22): e368-e454. DOI: 10.1161/CIR.0000000000001029.

9.Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial[J]. Circulation, 2020, 141(23): 1841-1854. DOI: 10.1161/CIRCULATIONAHA.120.046448.

10.Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes[J]. Eur Heart J, 2009, 30(10): 1195-1202. DOI: 10.1093/eurheartj/ehp099.

11.Selvaraj S, Steg PG, Elbez Y, et al. Pulse pressure and risk for cardiovascular events in patients with atherothrombosis: from the REACH registry[J]. J Am Coll Cardiol, 2016, 67(4): 392-403. DOI: 10.1016/j.jacc.2015.10.084.

12.Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44(7): 2064-2089. DOI: 10.1161/STR.0b013e318296aeca.

13.Khandelwal P, Yavagal DR, Sacco RL. Acute ischemic stroke intervention[J]. J Am Coll Cardiol, 2016, 67(22): 2631-2644. DOI: 10.1016/j.jacc.2016.03.555.

14.Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study[J]. Stroke, 2004, 35(10): 2263-2269. DOI: 10.1161/01.STR.0000142374.33919.92.

15.Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies[J]. Lancet, 2010, 375(9725): 1536-1544. DOI: 10.1016/S0140-6736(10)60319-4.

16.Desvarieux M, Demmer RT, Rundek T, et al. Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST)[J]. Stroke, 2003, 34(9): 2120-2125. DOI: 10.1161/01.STR.0000085086.50957.22.

17.Dong C, Rundek T, Wright CB, et al. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study[J]. Circulation, 2012, 125(24): 2975-2984. DOI: 10.1161/CIRCULATIONAHA.111.081083.

18.Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J]. N Engl J Med, 2009, 360(10): 961-972. DOI: 10.1056/NEJMoa0804626.

19.Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial[J]. Lancet, 2013, 381(9867): 629-638. DOI: 10.1016/S0140-6736(13)60141-5.

20.Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease[J]. N Engl J Med, 2016, 375(23): 2223-2235. DOI: 10.1056/NEJMoa1610227.

21.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial[J]. Lancet, 2002, 360(9326): 7-22. DOI: 10.1016/S0140-6736(02)09327-3.

22.Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes[J]. JAMA, 1995, 274(13): 1049-1057. DOI: 10.1001/jama.1995.03530130055028.

23.Libby P. The changing landscape of atherosclerosis[J]. Nature, 2021, 592(7855): 524-533. DOI: 10.1038/s41586-021-03392-8.

24.Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. BMJ, 2000, 321(7258): 405-412. DOI: 10.1136/bmj.321.7258.405.

25.Krishnan KR. Biological risk factors in late life depression[J]. Biol Psychiatry, 2002, 52(3): 185-192. DOI: 10.1016/s0006-3223(02)01349-5.

26.Dong JY, Zhang YH, Tong J, et al. Depression and risk of stroke: a meta-analysis of prospective studies[J]. Stroke, 2022, 43(1): 32-37. DOI: 10.1161/STROKEAHA.111.630871.

27.Gan Y, Gong Y, Tong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies[J]. BMC Psychiatry, 2014, 14: 371. DOI: 10.1186/s12888-014-0371-z.

28.Gill D, Monori G, Georgakis MK, et al. Genetically determined platelet count and risk of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol, 2018, 38(12): 2862-2869. DOI: 10.1161/ATVBAHA.118.311804.

29.Musunuru K, Post WS, Herzog W, et al. Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease[J]. Circ Cardiovasc Genet, 2010, 3(5): 445-453. DOI: 10.1161/CIRCGENETICS.109.923508.

30.Kumar M, Yan P, Kuchel GA, et al. Cellular senescence as a targetable risk factor for cardiovascular diseases: therapeutic implications: JACC family series[J]. JACC Basic Transl Sci, 2024, 9(4): 522-534. DOI: 10.1016/j.jacbts.2023.12.003.

31.Hamczyk MR, Nevado RM, Barettino A, et al. Biological versus chronological aging: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 75(8): 919-930. DOI: 10.1016/j.jacc.2019.11.062.

32.Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults[J]. Circulation, 2005, 111(25): 3384-3390. DOI: 10.1161/CIRCULATIONAHA.104.483628.

33.Touboul PJ, Elbaz A, Koller C, et al. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators[J]. Circulation, 2000, 102(3): 313-318. DOI: 10.1161/01.cir.102.3.313.

34.Ungvari Z, Tarantini S, Sorond F, et al. Mechanisms of vascular aging, a geroscience perspective: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 75(8): 931-941. DOI: 10.1016/j.jacc.2019.11.061.

35.Amarenco P, Goldstein LB, Sillesen H, et al. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Stroke, 2010, 41(3): 426-430. DOI: 10.1161/STROKEAHA.109.564781.

36.Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials[J]. Lancet, 2015, 385(9976): 1397-1405. DOI: 10.1016/S0140-6736(14)61368-4.

37.Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova  B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841): 581-590. DOI: 10.1016/S0140-6736(12)60367-5.

38.Choi SE, Bucci T, Huang JY, et al. Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: a propensity-matched analysis of a global federated health database[J]. Eur Stroke J, 2025, 10(1): 116-127. DOI: 10.1177/23969873241274213.

39.Li C, Bai C, Wang L, et al. Association between healthy lifestyle and cognitive decline, all-cause mortality, and mortality from cardiovascular and cerebrovascular diseases: a 10-year population-based prospective cohort study[J]. Alzheimers Dement, 2025, 21(3): e70021. DOI: 10.1002/alz.70021.

40.Cortes-Canteli M, Gispert JD, Salvadó G, et al. Subclinical atherosclerosis and brain metabolism in middle-aged individuals: the PESA study[J]. J Am Coll Cardiol, 2021, 77(7): 888-898. DOI: 10.1016/j.jacc.2020.12.027.

41.Testai FD, Gorelick PB, Chuang PY, et al. Cardiac contributions to brain health: a scientific statement from the American Heart Association[J]. Stroke, 2024, 55(12): e425-e438. DOI: 10.1161/STR.0000000000000476.

42.Loika Y, Loiko E, Culminskaya I, et al. Exome-wide association study identified clusters of pleiotropic genetic associations with Alzheimer's disease and thirteen cardiovascular traits[J]. Genes (Basel), 2023, 14(10): 1834. DOI: 10.3390/genes14101834.